Effect [qlco]
lornoxicam [orch, phsu]
Inflammatory [ftcn]
Marker [clna]
Non [ftcn]
ST segment elevation [fndg]
Acute Coronary Syndrome [dsyn]
Aim [idcn]
To [qlco]
Evaluate [ftcn]
Clinical [qlco]
Efficacy [qlco]
Safety [hcpp]
effects [qlco]
Non-steroidal anti-inflammatory drug [phsu]
lornoxicam [orch, phsu]
Inflammatory [ftcn]
Marker [clna]
Non [ftcn]
ST segment elevation [fndg]
Acute Coronary Syndrome [dsyn]
Subject [grup]
Methods [inpr]
Five [qnco]
Patients [podg]
Study, Prospective [resa]
randomized [resa]
divided [ftcn]
Group [idcn]
Patients [podg]
Received [qlco]
lornoxicam [orch, phsu]
mg% [qnco]
Daily [tmco]
days [tmco]
Standard [qlco]
treatment [ftcn]
Control [grup]
CARDIOVASCULAR [bdsy]
Outcome [ftcn]
Levels [qlco]
C-reactive protein [aapp, imft]
Result [ftcn]
lornoxicam [orch, phsu]
Group [idcn]
Exhibit [inpr]
reduction [npop]
C-reactive protein [aapp, imft]
Decrease [qlco]
Increase [ftcn]
Levels [qlco]
Group [idcn]
month [tmco]
Follow-up [fndg]
Indicated [fndg]
reduction [npop]
cardiovascular events [fndg]
Myocardial Infarction [dsyn]
Angina, Unstable [dsyn]
coronary [bpoc]
Death [orgf]
Conclusion [idcn]
lornoxicam [orch, phsu]
Risk [qlco]
Poor [grpa]
CARDIOVASCULAR [bdsy]
Outcome [ftcn]
Patients [podg]
Non [ftcn]
ST segment elevation [fndg]
Acute Coronary Syndrome [dsyn]
Levels [qlco]
Inflammatory [ftcn]
Marker [clna]
